Latest News
Construction Industry Random Drug Testing: Cost-Benefit Analysis for Safety Programs
Procurement-grade analysis of construction random drug testing: OSHA post-accident rules, recommended random rates, per-worker cost modeling, and supply planning.
How Pain Clinics Stay DEA Compliant: Drug Testing Protocols for Controlled Substance Prescribers
Risk-stratified UDM protocols for DEA-registered pain clinics. Frequency tables, panel selection, MRO review, and procurement guidance for compliance officers.
Treatment Center Drug Screening Programs: Volume Pricing and Subscribe-and-Save Math
Treatment center drug testing economics: volume pricing, phase-based frequency, 42 CFR Part 2 compliance, subscribe-and-save math for SUD programs.
Drug Testing Procurement RFP Template: Sample Specifications for Federal Buyers
Federal RFP template for drug testing procurement. GSA Schedule vs open-market vs simplified acquisition, FAR Part 12/13/15 compliance, sample specs.
DOT Drug Testing Requirements 2026: What Every Fleet Manager Needs to Know
Complete 2026 DOT drug testing compliance guide for fleet managers: 49 CFR Part 40, six required testing scenarios, Clearinghouse, MRO,...
How to Build a Compliant Workplace Drug Testing Program: Complete Procurement Guide
Procurement-grade blueprint for non-DOT workplace drug testing programs: policy, panels, vendor evaluation, cost modeling, and defensibility under state law.
FDA 510(k) Cleared vs Investigational Drug Tests: A Procurement Risk Guide
FDA 510(k) Cleared vs Investigational vs Research Use Only drug tests. Procurement risk, intended use, liability exposure, regulatory pathways explained.
Chain of Custody for Court-Defensible Drug Testing: A Step-by-Step Procurement Checklist
Procurement checklist for court-defensible chain of custody in drug testing. DOT vs non-DOT vs forensic standards, FRE 901/902, COC form...
CLIA-Waived vs Lab-Based Drug Testing: Cost & Compliance Comparison for Hospitals
Hospital procurement comparison of CLIA-waived, moderate-complexity, high-complexity, and send-out drug testing: cost, turnaround, accuracy, and regulatory burden.
